A Phase 3 interventional study of HCP1803-3 and HCP1803-4 in Hypertension, sponsored by Hanmi Pharmaceutical Company Limited. Not yet recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-06-30.
Sponsored by Hanmi Pharmaceutical Company Limited · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Hypertension by Hanmi Pharmaceutical Company Limited — 2 open to participants now, 2 under way, 1 of them phase 3. Hypertension · Hanmi Pharmaceutical Company Limited.
Among the 25 studies in Hypertension by Hanmi Pharmaceutical Company Limited, this one is the 5th largest by planned enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2026, is one of 16 in phase 3, and was the 24th registered.
6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.
Browse Hypertension studies →2 of the 25 studies in Hypertension by Hanmi Pharmaceutical Company Limited are open now, in 1 country. Recruiting first, the newest first:
Hanmi Pharmaceutical Company Limited · Sites in Korea, Republic of
By country, each count listing its studies:
Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 256 is above the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 199 across the 23 interventional studies, 4,450 across the 2 observational. Of the 23 that completed or were terminated, 1 (4%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hanmi Pharmaceutical Company Limited is the lead sponsor of 191 studies on the registry; 12 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.
1 of the studies in Hypertension by Hanmi Pharmaceutical Company Limited that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07660796Phase 3Hanmi Pharmaceutical Company LimitedA Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension | 2027-10-30 |
Add it to your calendar (.ics) → With an account.
Among the 25 studies in Hypertension by Hanmi Pharmaceutical Company Limited, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension
A multicenter, randomized, double-blind, phase III study to evaluate efficacy and safety of HCP1803-4 in patients with essential hypertension
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with essential hypertension whose blood pressure measured in visit1 corresponds to the following conditions
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Take HCP1803-3 once daily for 2 weeks orally, and then take HCP1803-4 once daily for 8 weeks orally.
Drug: HCP1803-3 · Drug: HCP1803-4
Take RLD2001-1 once daily for 2 weeks orally, and then take RLD2001-2 once daily for 8 weeks orally.
Drug: RLD2001-1 · Drug: RLD2001-2
Test drug
Test drug
Control drug
Control drug
Change from baseline in sitting systolic blood pressure
Time frame: Baseline, 10 weeks
Change from baseline in sitting systolic blood pressure
Time frame: Baseline, 2 weeks, 6 weeks
Change from baseline in sitting diastolic blood pressure
Time frame: Baseline, 2 weeks, 6 weeks, 10 weeks
Proportion of subjects achieving blood pressure control (sitSBP)
Time frame: 2 weeks, 6 weeks, 10 weeks
Proportion of subjects achieving blood pressure control (sitSBP, sitDBP)
Time frame: 2 weeks, 6 weeks, 10 weeks
Blood pressure response rate (sitSBP)
Time frame: 2 weeks, 6 weeks, 10 weeks
Blood pressure response rate (sitSBP, sitDBP)
Time frame: 2 weeks, 6 weeks, 10 weeks
Treatment response rate
Time frame: 2 weeks, 6 weeks, 10 weeks
Change from baseline in pulse pressure
Time frame: Baseline, 2 weeks, 6 weeks, 10 weeks
Start is estimated for Jul 2026; primary completion for Oct 2027, 15 months later.
Of 95 industry-sponsored phase 3 interventional studies under Hypertension, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's planned 15 months is below that.
Counting every sponsor, half of 141 studies reached it within 21 months; a quarter within 12 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hanmi Pharmaceutical Company Limited →